Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Clinical Trial to Evaluate Security and Dose of Expanded and Activated Autologous NK Cells Infusions in Consolidation of Multiple Myeloma Patients Treatment on Second or Later Relapse.

NCT02481934 is registered in ClinicalTrials.gov with Joaquín Martínez López, MD, PhD as lead sponsor.

NCT NCT02481934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02481934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Clinical Trial to Evaluate Security and Dose of Expanded and Activated Autologous NK Cells Infusions in Consolidation of Multiple Myeloma Patients Treatment on Second or Later Relapse.
Lead sponsor
Joaquín Martínez López, MD, PhD
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2013
Completion date
October 31, 2016
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma